



University Heart Center Hamburg



GERMAN AORTIC CENTER HAMBURG



## How Does The ASA-Score And Sarcopenia Influence SCI Risk After Endovascular TAAA repair?

Tilo Köhler, Petroula Nana, Konstantinos Spanos

German Aortic Center Hamburg  
 Dep. Of Vascular Diseases  
 University Heart & Vascular Center  
 University Medical Center Eppendorf



Tuesday - Saturday, November 19-23, 2024




## Disclosures




- Consultant: Cook Medical, Philips, Gefinge, Terumo Aortic, Arterica
- Research-grants: Cook Medical, Philips, Terumo Aortic, Medtronic
- Travel-grants: Cook Medical, Gefinge, Philips
- Speaking fees: Cook Medical, Philips, Gefinge
- Shares: Mokita-Medical, Arterica
- IP: Cook Medical, Terumo Aortic, Mokita Medical
- Royalties: Cook Medical, Terumo Aortic

• Devices and Techniques in this presentation are not approved by the FDA




## SCI in Complex Endovascular Aortic Repair




Extended coverage (TAAA HV):


- \* All SCI: 4.5 - 20.5%
- \* Grade 3 SCI (Paraplegia): 2.0-2.9%
- \* Permanent Grade 3: 1.5%
- \* Elective vs. Urgent: No significant difference



Locatelli, et al. J Vasc Surg. 2023; 78:883-91.  
 Nana, et al. 2024. J Vasc Surg. 2024;79:457-46.e2.  
 Abdelrahim, et al. J Vasc Surg. 2023; 78:834-42.



## Risk Factors For SCI



- \* Extend of aortic coverage
- \* Intraoperative blood loss
- \* Early and later experience
- \* **Sarcopenia**
- \* Degenerative aneurysms
- \* Persistent neuromonitoring changes

Bisdas, et al. J Vasc Surg. 2015;61:1408-16.  
 Spanos, et al. J Vasc Surg. 2019;69:357-66.  
 Teramo, et al. 2021. Ann Surg. 2021;276:1028-34.  
 Nana, et al. Eur J Vasc Endovasc Surg. 2023;65:503-12.  
 Potter, et al. J Vasc Surg. 2024;80:656-64.




## Sarcopenia Definition





- \* Progressive and generalized skeletal muscle disorder
- \* More common among older adults
- \* Low muscle quality and quantity
- \* Severe sarcopenia → poor physical performance
- \* Associated with falls, fractures, mortality

Kirk, et al. Age Ageing. 2024;48:16-31  
 Cruz-Jentoft, et al. Age Ageing. 2024;48:16-31




## Detection Of Sarcopenia



- \* Questionnaires (SARC-F)
- \* Physical tests (grip strength, Chair stand test)
- \* Imaging studies [Dual-energy X-ray Absorptiometry (DXA) or Bioelectrical Impedance Analysis (BIA)]

↓

- \* Lumbar muscle cross-sectional area by CT or MRI



Cruz-Jentoft, et al. Age Ageing. 2019;48:16-31

### Psoas & Erector Spinae Muscle Area

**ESMA – Erector Spinae Muscle Area – cm<sup>2</sup>**

**LESMA – Lean Erector Spinae Muscle Area cm<sup>2</sup> x Hounsfield Units**

Kärkkäinen, et al. J Vasc Surg. 2021;73:1178-88  
 Enzmann, et al. J Vasc Surg. 2024; Under Review.

### Muscle Loss After F/BEVAR

Hamburg Data: 103 patients with TAAA

**PMA & ESMA decreased after F/BEVAR (p < .001)**

**LPMA & LESMA decreased after F/BEVAR (p < .001)**

Enzmann, et al. J Vasc Surg. 2024; Under Review.

### Sarcopenia & Complex Aortic Repair

Metanalysis including 1 092 patients managed with complex aortic repair

- Preoperative sarcopenia did not predict mortality
- Significantly higher 30-day mortality in sarcopenic patients (25% vs 13%)

**Heterogenic sarcopenia definitions**

**Different cut-off values**

Figure 3. Forest plot of the sarcopenia related mid-term mortality rate in patients managed for complex aortic aneurysms.

Nana et al. 2023; Eur J Vasc Endovasc Surg 65:503-12

### Sarcopenia & SCI

- Retrospective study of 257 F/BEVAR patients
- Total Psoas Muscle Area associated with 30-day SCI

Alezei, et al. Cardiovasc Interv Radiol. 2021;44:376-83.

- Metanalysis with mixed population (F/BEVAR and OSR)
- SCI higher in sarcopenic patients (19% vs. 7%) independent of TAAA extend

Figure 4. Forest plot of the sarcopenia related 30 day rate of spinal cord ischemia in patients managed for complex aortic aneurysms.

Nana et al. 2023; Eur J Vasc Endovasc Surg 65:503-12

### Sarcopenia & ASA As Predictors Of Mortality

Psoas muscle area and attenuation are highly predictive of complications and mortality after complex endovascular aortic repair

- Single center 2007-2019; n=504
- F/BEVAR for pAAA & TAAA
- LPMA & ASA combined risk groups

Kärkkäinen et al. J Vasc Surg. 2021;73:1178-88.

### Sarcopenia & ASA As Predictors Of SCI


**The Association of Sarcopenia and ASA Score to Spinal Cord Ischemia in Patients Treated With the t-Branch Device**

Single center 2018-2020; n=80

- TAAA: 72.5%
- TAAA HIII: 42.5%
- Urgent repair: 46%
- Mortality (30d): 14%
- SCI (grade 1-3): 15%

Parameter	Value
Age	71
Male	55
Aneurysm diameter (mm)	64.6-16.0
Aneurysm type	
Thoracoabdominal	58
Type I	9
Type II	9
Type III	9
Type IV	17
Type V	7
Para-lymphatic	22
Ischemic heart disease	25
Hypertension	65
Dyslipidemia	19
Smoking	29
Chronic obstructive pulmonary disease	20
Diabetes mellitus type II	6
PAD	3
CVD	4
Chronic kidney disease	24
Previous aortic intervention	35
Body mass index (kg/m <sup>2</sup> )	23.7
Psoas muscle area (cm <sup>2</sup> )	7.5±2.8
Psoas muscle attenuation (HU)	24.3±11.6
LPMA (cm <sup>2</sup> HU)	27.7±14.0

Köbel, et al. J Endovasc Ther. 2023; Online ahead of print.



### LPMA As Predictor Of SCI

**A**

LPMA stratification	Group 1 (n=18)	Group 2 (35)	Group 3 (n=27)	P < .05
<b>Baseline characteristics</b>				
Age	64.3	64.1	73.5	0.02
BMI	26.4	25.7	24.5	0.6
VO2 max	14	16	11	0.003
Aneurysm diameter	6.8	6.6	7.1	0.68
<b>Medical History</b>				
Ischemic heart disease	5	9	11	0.45
Hypertension	14	29	22	0.78
Dyslipidemia	5	8	6	0.9
Tobacco use	6	13	9	0.9
Diabetes type II	1	1	5	0.44
Chronic kidney disease	3	13	8	0.34
Preformed aortic disease	4	4	1	0.15
Previous cardiac intervention	9	14	13	0.78
<b>Early main outcomes</b>				
Mortality	2	2	8	0.32
SCI	1	5	6	0.28

Kölbel, et al., J Endovasc Ther., 2023; Online ahead of print.

### LPMA & ASA As Predictor Of SCI

**B**

Patients' risk classification with ASA-LPMA	Low (28)	Medium (14)	High (34)	P Value (<.05)
Age	67.1±2	72.1±8	73.5±4	0.04
BMI	26.3±4	24.2±4	25.5±5	0.33
Sex	24	10	16	0.003
Spinal drainage	19	10	25	0.88
<b>Early outcomes</b>				
Mortality	3	2	7	0.59
SCI	1	2	9	0.049

- \* SCI: 3.5% low vs. 12.5% moderate vs. 25% high (p=.049)
- \* Multivariate: moderate risk group related to SCI (p=.04)

Kölbel, et al., J Endovasc Ther., 2023; Online ahead of print.

- ### Summary
- \* Patients with ASA score I-II or LPMA > 350cm<sup>2</sup>HU, are at low risk for SCI after BEVAR with t-Branch
  - \* Combination of ASA & LPMA may identify a higher risk group for SCI
  - \* Further data needed